remimazolam 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
diazepam derivatives 5400 308242-62-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • remimazolam
  • remimazolam besylate
  • byfavo
  • CNS 7056
  • CNS 7056B
  • ONO-2745BS
  • ONO-2745
  • anerem
  • aptimyda
Remimazolam is a benzodiazepine and it binds to brain benzodiazepine sites (gamma amino butyric acid type A [GABAA] receptors), while its carboxylic acid metabolite (CNS7054) has a 300 times lower affinity for the receptor. Remimazolam, like other benzodiazepines, did not show clear selectivity between subtypes of the GABAA receptor.
  • Molecular weight: 439.31
  • Formula: C21H19BrN4O2
  • CLOGP: 2.81
  • LIPINSKI: 0
  • HAC: 6
  • HDO: 0
  • TPSA: 69.37
  • ALOGS: -4.31
  • ROTB: 5
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
S (Water solubility) 8.30 mg/mL Bocci G, Oprea TI, Benet LZ
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Bocci G, Oprea TI, Benet LZ

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 2.619 High 1
caco2-efflux Caco-2 efflux ratio (BA/AB) 1.064 High 1
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 49.091 10^-6 cm/s High 1
dh-clint Dog hepatocyte intrinsic clearance 84.333 uL/min/10^6 cells High 1
dppb Dog plasma protein binding (% unbound) 17.820 % High 1
fcs-ppb Fetal calf serum protein binding (% unbound) 28.800 % High 1
herg hERG pIC50 4.602 pIC50 High 1
hh-clint Human hepatocyte intrinsic clearance 118.850 uL/min/10^6 cells High 1
hlm-clint Human liver microsomal intrinsic clearance 154.525 uL/min/mg protein High 1
hppb Human plasma protein binding (% unbound) 14.010 % High 1
kinase-safety-class ACVR2B,AXL,BRAF,CAMK2B,CAMK2D,CDK5,CDK9,DYRK1B,EIF2AK3,ERBB2,GRK2,GSK3B,ITK,MAP3K21,MAP3K7,MAPK10,MAPK7,MARK4,PDK1,PDK2,PDK4,PIK3CB,PIK3CD,PIK3CG,PRKDC,STK33,TEK,TTK 28
kinase-selectivity-class ACVR2B,AXL 2
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 1.023 High 1
mh-clint Mouse hepatocyte intrinsic clearance 429.536 High 1
mppb Mouse plasma protein binding (% unbound) 16.760 High 1
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 2.265 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 29.950 % High 1
rh-clint Rat hepatocyte intrinsic clearance 295.801 uL/min/10^6 cells High 1
rh-fuinc Rat hepatocyte fraction unbound in incubation 80.360 % High 1
rppb Rat plasma protein binding (% unbound) 14.690 % High 1
solubility-dd Solubility at pH 7.4 in DMSO 674.528 uM High 1

Approvals:

DateAgencyCompanyOrphan
July 2, 2020 FDA ACACIA
Jan. 23, 2020 PMDA Anerem
March 26, 2021 EMA PAION Netherlands B.V.

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Anaphylactic shock 113.50 109.64 24 156 51522 110537597

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N05CD14 NERVOUS SYSTEM
PSYCHOLEPTICS
HYPNOTICS AND SEDATIVES
Benzodiazepine derivatives
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:38070 anti-arrhythmia drug
CHEBI has role CHEBI:38867 anaesthetic
CHEBI has role CHEBI:48407 antiparkinson drug
CHEBI has role CHEBI:35480 analgesic
CHEBI has role CHEBI:35717 sedative

Related Drugs by ATC class:

N05CD Benzodiazepine derivatives 14 drugs
brotizolamcinolazepamdoxefazepamestazolamflunitrazepamflurazepamloprazolamlormetazepammidazolamnimetazepamnitrazepamquazepam show all 14 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Sedation indication 72641008
Non-allergic hypersensitivity to dextran contraindication 609536007




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 20MG BASE/VIAL BYFAVO ACACIA N212295 Oct. 6, 2020 RX POWDER INTRAVENOUS 10472365 July 10, 2027 USE OF REMIMAZOLAM FOR INDUCTION AND MAINTENANCE OF PROCEDURAL SEDATION IN ADULTS UNDERGOING PROCEDURES LASTING 30 MINUTES OR LESS
EQ 20MG BASE/VIAL BYFAVO ACACIA N212295 Oct. 6, 2020 RX POWDER INTRAVENOUS 10961250 July 10, 2027 USE OF REMIMAZOLAM FOR INDUCTION AND MAINTENANCE OF PROCEDURAL SEDATION IN ADULTS UNDERGOING PROCEDURES LASTING 30 MINUTES OR LESS
EQ 20MG BASE/VIAL BYFAVO ACACIA N212295 Oct. 6, 2020 RX POWDER INTRAVENOUS 10052334 Nov. 7, 2031 USE OF REMIMAZOLAM FOR INDUCTION AND MAINTENANCE OF PROCEDURAL SEDATION IN ADULTS UNDERGOING PROCEDURES LASTING 30 MINUTES OR LESS
EQ 20MG BASE/VIAL BYFAVO ACACIA N212295 Oct. 6, 2020 RX POWDER INTRAVENOUS 10195210 Nov. 7, 2031 USE OF REMIMAZOLAM FOR INDUCTION AND MAINTENANCE OF PROCEDURAL SEDATION IN ADULTS UNDERGOING PROCEDURES LASTING 30 MINUTES OR LESS
EQ 20MG BASE/VIAL BYFAVO ACACIA N212295 Oct. 6, 2020 RX POWDER INTRAVENOUS 10342800 Nov. 7, 2031 USE OF REMIMAZOLAM FOR INDUCTION AND MAINTENANCE OF PROCEDURAL SEDATION IN ADULTS UNDERGOING PROCEDURES LASTING 30 MINUTES OR LESS
EQ 20MG BASE/VIAL BYFAVO ACACIA N212295 Oct. 6, 2020 RX POWDER INTRAVENOUS 10722522 Nov. 7, 2031 USE OF REMIMAZOLAM FOR INDUCTION AND MAINTENANCE OF PROCEDURAL SEDATION IN ADULTS UNDERGOING PROCEDURES LASTING 30 MINUTES OR LESS
EQ 20MG BASE/VIAL BYFAVO ACACIA N212295 Oct. 6, 2020 RX POWDER INTRAVENOUS 9737547 Nov. 7, 2031 USE OF REMIMAZOLAM FOR INDUCTION AND MAINTENANCE OF PROCEDURAL SEDATION IN ADULTS UNDERGOING PROCEDURES LASTING 30 MINUTES OR LESS
EQ 20MG BASE/VIAL BYFAVO ACACIA N212295 Oct. 6, 2020 RX POWDER INTRAVENOUS 9561236 April 30, 2033 USE OF REMIMAZOLAM FOR INDUCTION AND MAINTENANCE OF PROCEDURAL SEDATION IN ADULTS UNDERGOING PROCEDURES LASTING 30 MINUTES OR LESS
EQ 20MG BASE/VIAL BYFAVO ACACIA N212295 Oct. 6, 2020 RX POWDER INTRAVENOUS 9827251 Jan. 13, 2034 USE OF REMIMAZOLAM FOR INDUCTION AND MAINTENANCE OF PROCEDURAL SEDATION IN ADULTS UNDERGOING PROCEDURES LASTING 30 MINUTES OR LESS

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
GABA-A receptor; benzodiazepine binding site Ion channel MODULATOR Ki 7.53 SCIENTIFIC LITERATURE DRUG LABEL
GABA A receptor alpha-3/beta-2/gamma-2 Ion channel MODULATOR EC50 6.04 SCIENTIFIC LITERATURE
GABA-A receptor; alpha-1/beta-2/gamma-2 Ion channel MODULATOR EC50 6.44 SCIENTIFIC LITERATURE
GABA A receptor alpha-2/beta-2/gamma-2 Ion channel MODULATOR EC50 6.18 SCIENTIFIC LITERATURE
GABA A receptor alpha-5/beta-2/gamma-2 Ion channel MODULATOR EC50 5.86 SCIENTIFIC LITERATURE

External reference:

IDSource
D11788 KEGG_DRUG
7V4A8U16MB UNII
1001415-66-2 SECONDARY_CAS_RN
4039938 VANDF
C3179470 UMLSCUI
CHEBI:757006 CHEBI
CHEMBL4297526 ChEMBL_ID
9867812 PUBCHEM_CID
DB12404 DRUGBANK_ID
CHEMBL4594301 ChEMBL_ID
9232 INN_ID
C522201 MESH_SUPPLEMENTAL_RECORD_UI
8442 IUPHAR_LIGAND_ID
926369003 SNOMEDCT_US
926383001 SNOMEDCT_US
926385008 SNOMEDCT_US
336210 MMSL
38618 MMSL
d09651 MMSL
018433 NDDF
018438 NDDF
2383941 RXNORM

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
BYFAVO HUMAN PRESCRIPTION DRUG LABEL 1 71390-011 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 2.50 mg INTRAVENOUS NDA 35 sections